Kenvue Inc. is dealing with another challenge to a top-selling product as it attempts to close its $40 billion acquisition by ...

Kimberly-Clark's latest valuation update reflects only a slight trim to its fair value estimate, nudging it from about ...

Kimberly-Clark (KMB) stock faces risks from the $48.7B Kenvue acquisition, high debt, and weak growth. Learn why analysts ...

"I will not allow Big Pharma to operate above the law or put their greed ahead of Texans’ well-being," said Paxton.

KVUE's stock performance has suffered from legacy investor selling, management turnover, litigation risks, and a profit ...

A Texas judge has ordered Tylenol-maker Kenvue Inc. and its former parent Johnson & Johnson to register with the Texas Secretary of State or risk being barred from doing business in the state.

Shares of Kenvue Inc. KVUE slid 1.04% to $17.10 Thursday, on what proved to be an all-around positive trading session for the ...

Kenvue has a lower P/E than the aggregate P/E of 55.57 of the Personal Products industry. Ideally, one might believe that the ...

Kenvue says that Thibaut Mongon is leaving as CEO as the maker of Listerine and Band-Aid brands continues with a strategic review of the company. Kenvue used to be a part of Johnson & Johnson. J&J ...

NEW YORK (Reuters) -Kenvue is exploring the sale of some of its skin health and beauty brands, four people familiar with the matter said on Thursday, as the consumer health firm prunes an ...

In what is being called one of the largest corporate takeovers in years, Kimberly-Clark is buying Tylenol parent company, Kenvue, reported AP, with the new company expected to generate about $32 ...

Kimberly-Clark will buy Kenvue for $48.7 billion. Kenvue is the maker of Tylenol. Kenvue just beat earnings in its Q3 2025 report. The good news for Kenvue is that the bad press didn't prevent the ...